Participants initially received secukinumab 75mg subcutaneously once every four weeks in the extension study. If the signs and symptoms of the participants were not adequately controlled with the 75mg dose, as determined by the investigator, the dose could be escalated to 150mg subcutaneously. For patients weighing 50kg and over, the dose could further be escalated to 300mg subcutaneously every four weeks. The dose escalation from secukinumab 75mg subcutaneously to 300mg subcutaneously was to be implemented in two steps, with the first step being an increase to 150mg subcutaneously, followed by another escalation to 300mg subcutaneously, based on the judgement of the investigator.

Secukinumab solution for subcutaneous injections was provided in PFS. Initially, participants continued to receive secukinumab at either 75 mg (in 0.5mL) or 150 mg (in 1mL) every 4 weeks, consistent with their dosage at the Week 100 visit of the core study. The dose could be escalated from 75 mg to 150 mg for patients whose signs and symptoms were not fully controlled, as judged by the investigator, with the current 75 mg dose. Furthermore, the dose could also be escalated to 300 mg every 4 weeks for patients weighing 50kg and over who were currently on the 150 mg dose and whose signs and symptoms were not well-controlled, as judged by the investigator. The dose escalation from secukinumab 75 mg to 300 mg was to be implemented in two steps (first 150 mg and then 300 mg based on the investigator's judgment). At each study treatment time point, one or two subcutaneous injections in the form of PFS were administered.

Secukinumab

Participants initially received secukinumab 150mg subcutaneously once every four weeks in the extension study. If the signs and symptoms of the participants were not adequately controlled with the 150mg dose, as determined by the investigator, the dose could be escalated to 300mg subcutaneously.

Pharmaceutically manufactured. Cannabidiol is formulated as a clear gel for transdermal delivery.

Pharmaceutically manufactured cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)

ZYN002 - transdermal gel

Placebo is formulated as a clear gel for transdermal delivery.

Placebo formulated as a clear gel that can be applied to the skin (transdermal delivery)

Other Names:

Placebo Comparator Matching Placebo

Placebo

Participants received ELX 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period approximately 13 weeks.

Fixed dose combination (FDC) tablet for oral administration.

ELX/TEZ/IVA

6 subjects each will receive RVP-001 at a dose of 2 mg Mn/kg

RVP-001

6 subjects each will receive RVP-001 at a dose of 7 mg Mn/kg

6 subjects each will receive RVP-001 at a dose of 12 mg Mn/kg

어린이 중증 근무력증 환자에게 라불리주맙 주사 치료의 몸 반응과 약물 동작을 살펴보는 연구입니다.

All participants will receive a weight-based loading dose of ravulizumab IV on Day 1, followed by weight-based maintenance dose of ravulizumab on Day 15 and once every 8 weeks (q8w) thereafter for participants weighing ≥ 20 kg, or once every 4 weeks (q4w) for participants weighing \< 20 kg, for a total of 122 weeks of treatment.

Ravulizumab will be administered by intravenous (IV) infusion.

Ravulizumab

Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.

Fixed-dose combination granules for oral administration.

Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening with the dose(s) to be based on the outcome of Part A.

Patients receive botensilimab IV, balstilimab IV, and regorafenib PO on study. Patients also undergo CT and collection of blood throughout the study.

Balstilimab

Biospecimen Collection

Botensilimab

Computed Tomography

Regorafenib

7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water

CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.

gold nanocrystals

15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water

30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water

60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water

XXB750 drug

Participants received LTP001, 6 mg, oral capsules, once daily in the morning for approximately 24 weeks

LTP001, 6 mg, was administered orally once daily in the morning

LTP001

Participants received LTP001 placebo capsules matching LTP001 orally once daily in the morning for approximately 24 weeks

Placebo to LTP001 was administered once daily in the morning

Participants will be randomized to receive ARO-ANG3 SC on Day 1 and Day 84 during the initial 36 Weeks of the study and on Day1 and Months 3, 6, 9, 12, 15, 18, and 21 of the extension period

ARO-ANG 3 Injection

Obese pts with hypertension, starting treatment with eplerenone 25mg twice daily (BD). ABPM wil be scheduled at wks 8, 16 and 24.

At wk 8 if mean ABPM \< 130/80mm Hg will continue to monotherapy with eplerenone. If not controlled (mean ABPM \> 130/80mm Hg) at wk8, amlodipine 5mg OD will be added.

At wk 16 if mean ABPM \< 130/80mm Hg will continue to monotherapy with eplerenone, or dual therapy with eplerenone and amlodipine. If not controlled (mean ABPM \> 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks.

At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.

Eplerenone (-based therapy) arm

Obese pts with hypertension, starting treatment with irbesartan 150mg once daily (OD). ABPM wil be scheduled at wks 8, 16 and 24.

At wk 8 if mean ABPM \< 130/80mm Hg will continue to monotherapy with irbesartan. If not controlled (mean ABPM \> 130/80mm Hg) at wk8, amlodipine 5mg OD will be added.

At wk 16 if mean ABPM \< 130/80mm Hg will continue to monotherapy with irbesartan, or dual therapy with irbesartan and amlodipine. If not controlled (mean ABPM \> 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks.

Valsartan (-based therapy) arm

Open label, single arm treatment with bbT369

bbT369 is a genetically modified autologous T cell immunotherapy product consisting of T cells that are transduced with a single lentiviral vector (LVV) to express anti-CD79a and anti-CD20 chimeric antigen receptors (CARs) and transfected with an mRNA encoding the CBLB-targeting megaTAL enzyme to edit the CBLB gene, suspended in a cryopreservative solution.

bbT369

Participants received LTP001, 6 mg, orally once daily in the morning for approximately 39 weeks

All participants will receive a weight-based loading dose of ravulizumab on Day 1, followed by weight-based maintenance treatment with ravulizumab on Day 15 and either once every 8 weeks (q8w) thereafter or once every 4 weeks (q4w) depending on weight.

Participants will receive Ravulizumab via intravenous (IV) infusion.

study eye treated with 100 μg (94.3 μg free acid) of OLX10212

Clear colorless solution dissolved in 1X PBS and injected intravitreally

OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)

study eye treated with 250 μg (235.8 μg free acid) of OLX10212

study eye treated with 500 μg (471.5 μg free acid) of OLX10212

study eye treated with 750 μg (707.3 μg free acid) of OLX10212

study eye treated with 950 μg (895.9 μg free acid) of OLX10212

study eye treated with a total of 3 intravitreal injections of 750 μg (707.3 μg free acid) of OLX10212 each 28 days apart

study eye treated with a total of 3 intravitreal injections of 950 μg (895.9 μg free acid) of OLX10212 each 28 days apart

DZD6008

Shum

The monotherapy group will be treated with the following treatments:

A) 1 to 2 weeks of Amlodipine 5mg followed by 6 to 7 weeks of Amlodipine 10mg B) 1 to 2 weeks of Lisinopril 10mg followed by 6 to 7 weeks of Lisinopril 20mg C) Approximately 8 weeks of 25mg Chlortalidone

Participants will be randomly allocated to one of six possible sequences of treatments of the three-treatment-three period Williams design: ABC, ACB, BAC, BCA, CAB, and CBA.

Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.

Amlodipine

Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.

Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm.

Lisinopril

Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.

Chlortalidone

The dual-therapy group will be treated with the following treatments:

A) Approximately 8 weeks of Amlodipine 5mg and Lisinopril 20mg B) Approximately 8 weeks of Amlodipine 5mg and Chlortalidone 25mg C) Approximately 8 weeks of Lisinopril 20mg and Chlortalidone 25mg D) Approximately 8 weeks of Amiloride 10mg and Chlortalidone 25mg

Participants will be randomly allocated to one of four possible sequences of treatments of the four-treatment four-period Williams design: ABDC, BCAD, CDBA, and DACB.

Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.

Amiloride

Cambridge University Hospitals NHS Foundation Trust

All eligible participants will be enrolled to receive \[18F\]CTT1057 imaging agent on Day 1 and have PET/CT scan

[18F]CTT1057

Cycles 1-6, q14 days Day 1: Methotrexate + Rituximab Days 6-14: Ibrutinib daily orally

세쿠키누맙

ZYN002 - 경피 젤, 위약

ELX/TEZ/IVA, 부가가치세

RVP-001

라불리주맙

ELX/TEZ/IVA, 부가가치세

발스틸리맙, 생체 시료 수집, 보텐실리맙, 컴퓨터 단층 촬영, 레고라페닙

금 나노결정

XXB750 약물, 위약

LTP001, 위약

아로앙 3 주사

에플레레논(-기반 치료)군, 발사르탄(-기반 치료)군

bbT369

LTP001

라불리주맙

OLX10212는 세포 투과성 비대칭 소형 간섭 RNA(cp-asiRNA)입니다.

디즈디6008

암로디핀, 리시노프릴, 아밀로라이드, 클로르탈리돈

[18F]CTT1057

메토트렉세이트, 리툭시맙(가능한 경우), 이브루티닙